# EDGAR Filing Document

**Accession Number:** 0001321732
**File Stem:** 0001321732-26-000018
**Filing Date:** 2026-5
**Character Count:** 15637
**Document Hash:** d35aaa62f8a9eb5f0c13d4bd2ab1266e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001321732-26-000018.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001321732-26-000018

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260506

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Penumbra Inc
- **CENTRAL INDEX KEY:** 0001321732
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37557
- **FILM NUMBER:** 26948589

**BUSINESS ADDRESS:**
- **STREET 1:** ONE PENUMBRA PLACE
- **CITY:** ALAMEDA
- **STATE:** CA
- **ZIP:** 94502
- **BUSINESS PHONE:** (510) 995-2486

**MAIL ADDRESS:**
- **STREET 1:** ONE PENUMBRA PLACE
- **CITY:** ALAMEDA
- **STATE:** CA
- **ZIP:** 94502

?xml version='1.0' encoding='ASCII'? pen-20260506

**__________________________________________________________________________________________________________________________**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**_______________________________________________________________________________________________________________________________**

**FORM 8-K** 

**_______________________________________________________________________________________________________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**May 6, 2026**

**Date of Report (Date of earliest event reported)** 

**_______________________________________________________________________________________________________________________________**

**Penumbra, Inc.**

**(Exact name of registrant as specified in its charter)**

_______________________________________________________________________________________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37557** | **05-0605598** |
| **(State or other jurisdiction of incorporation or organization)** | **(Commission File No.)** | **(I.R.S. employer identification number)** |

---

**One Penumbra Place**

**Alameda, CA 94502**

**(Address of principal executive offices, including zip code)**

**(510) 748-3200**

**(Registrant's telephone number, including area code)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol</u>** | **<u>Name of each exchange on which registered</u>** |
| Common Stock, Par value $0.001 per share | PEN | The New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

**_______________________________________________________________________________________________________________________________**

------

**_______________________________________________________________________________________________________________________________**

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition.** |

---

On May 6, 2026, Penumbra, Inc. issued a press release announcing financial results for the first fiscal quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished on this Current Report on Form 8-K, including the attached exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| <u>Exhibit Number</u> | <u>Description</u> |
| <u>[99.1](pen-33126xexhibit991.htm)</u> | Press release of Penumbra, Inc. dated May 6, 2026. |
| 104 | Cover Page Interactive Data File (formatted as Inline Extensible Business Reporting Language). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Penumbra, Inc.** | **Penumbra, Inc.** |
| Date: May 6, 2026 | By: | /s/ Maggie Yuen |
|  |  | Maggie Yuen |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**<u>Exhibit 99.1</u>**

![image1a.jpg](image1a.jpg)

**Penumbra, Inc. Reports First Quarter 2026 Financial Results**

ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Income from operations of $38.2 million and net income of $32.6 million in the first quarter of 2026.**

**Full Year 2026 Financial Outlook and Webcast and Conference Call Information**

Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended March 31, 2026.

**About Penumbra**

Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit <u>www.penumbrainc.com</u> and connect on <u>Instagram, LinkedIn, and X</u>.

**Forward-Looking Statements**

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

------

 **Penumbra, Inc.**

**Condensed Consolidated Balance Sheets**

**(unaudited)**

**(in thousands)**

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | $241289 | $186897 |
| &nbsp;&nbsp;&nbsp;&nbsp; Marketable investments | 374371 | 357919 |
| &nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable, net | 183295 | 190021 |
| &nbsp;&nbsp;&nbsp;&nbsp; Inventories | 438539 | 431549 |
| &nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses and other current assets | 37912 | 50298 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | 1275406 | 1216684 |
| Property and equipment, net | 134059 | 117436 |
| Operating lease right-of-use assets | 170273 | 173587 |
| Finance lease right-of-use assets | 25209 | 25972 |
| Intangible assets, net | 5946 | 6186 |
| Goodwill | 166589 | 166750 |
| Deferred taxes | 79972 | 79188 |
| Other non-current assets | 40984 | 40716 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $1898438 | $1826519 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | $43658 | $34736 |
| &nbsp;&nbsp;&nbsp;&nbsp; Accrued liabilities | 151543 | 132163 |
| &nbsp;&nbsp; Current operating lease liabilities | 14144 | 13841 |
| &nbsp;&nbsp; Current finance lease liabilities | 2386 | 2393 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | 211731 | 183133 |
| Non-current operating lease liabilities | 179424 | 182751 |
| Non-current finance lease liabilities | 20221 | 20714 |
| Other non-current liabilities | 13250 | 12318 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | 424626 | 398916 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock | 39 | 39 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 1201423 | 1185525 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 2075 | 4348 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 270275 | 237691 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 1473812 | 1427603 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1898438 | $1826519 |

---

------

**Penumbra, Inc.**

**Condensed Consolidated Statements of Operations**

**(unaudited)**

**(in thousands, except share and per share amounts)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenue | $374758 | $324140 |
| Cost of revenue | 121347 | 108257 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 253411 | 215883 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 22382 | 22077 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales, general and administrative | 192795 | 153456 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 215177 | 175533 |
| Income from operations | 38234 | 40350 |
| Interest and other income, net | 3454 | 3508 |
| Income before income taxes | 41688 | 43858 |
| Provision for income taxes | 9104 | 4635 |
| Net income | $32584 | $39223 |
| Net income per share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.83 | $1.02 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.82 | $1.00 |
| Weighted average shares outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 39275424 | 38562191 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 39543780 | 39163428 |

---

------

**Penumbra, Inc.**

**Reconciliation of Revenue Growth by Geographic Regions**

**(unaudited)**

**(in thousands, except for percentages)**

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Change** |
| | **2026** | **2025** | $**%** |
| United States | $296387 | $256860 | 15.4% |
| International | 78371 | 67280 | 16.5% |
| Total | $374758 | $324140 | 15.6% |

---

**Penumbra, Inc.**

**Reconciliation of Revenue Growth by Product Categories**

**(unaudited)**

**(in thousands, except for percentages)**

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Change** |
| | **2026** | **2025** | $**%** |
| Thrombectomy | $253917 | $226544 | 12.1% |
| Embolization and Access | 120841 | 97596 | 23.8% |
| Total | $374758 | $324140 | 15.6% |

---

**Investor Relations**

Penumbra, Inc.

<u>investors@penumbrainc.com</u>

Source: Penumbra, Inc.

<br>